clinical trial · NCT04908176
A Drug-drug Interaction Study of Avapritinib and Midazolam
Gastrointestinal Stromal TumorsGISTNon-resectable Advanced Solid TumorsRecurrent or Unresectable Central Nervous System (CNS) TumorsAvapritinibmidazolam
brief summary
The purpose of this study is to investigate the effect of multiple dosing of avapritinib on the pharmacokinetics (PK) of midazolam in adult patients with metastatic or unresectable gastrointestinal stromal tumors (GIST), recurrent gliomas, or other KIT mutant tumors.
started
Aug 24, 2022
primary completion
Mar 1, 2024
completion
May 10, 2024
last updated
Dec 13, 2024
official title
A Drug-drug Interaction Study to Investigate the Effect of Avapritinib on the Pharmacokinetics of Midazolam in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST) and Other Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol